{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:42:09Z","timestamp":1791895329452,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Filoviruses, including ebolaviruses and marburgviruses, can cause severe and often fatal disease in humans. Over the past several years, antibody therapy has emerged as a promising strategy for the treatment of filovirus disease. Here, we describe 2 distinct cross-reactive monoclonal antibodies (mAbs) isolated from mice immunized with recombinant vesicular stomatitis virus\u2013based filovirus vaccines. Both mAbs recognized the glycoproteins of multiple different ebolaviruses and exhibited broad but differential in vitro neutralization activities against these viruses. By themselves, each mAb provided partial to full protection against Ebola virus in mice, and in combination, the mAbs provided 100% protection against Sudan virus challenge in guinea pigs. This study identified novel mAbs that were elicited through immunization and able to provide protection from ebolavirus infection, thus enriching the pool of candidate therapeutics for treating Ebola disease.<\/jats:p>","DOI":"10.1093\/infdis\/jiad205","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T09:37:41Z","timestamp":1686217061000},"page":"S691-S700","source":"Crossref","is-referenced-by-count":17,"title":["A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses"],"prefix":"10.1093","volume":"228","author":[{"given":"Guodong","family":"Liu","sequence":"first","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"He","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chan","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Schulz","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Cao","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Niaz","family":"Rahim","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Audet","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Garnett","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wec","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangguo","family":"Qiu","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-2648","authenticated-orcid":false,"given":"Logan","family":"Banadyga","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2024041206144034400_jiad205-B1","first-page":"450","volume-title":"Fields virology: emerging viruses","author":"Kuhn","year":"2021","edition":"7th ed"},{"key":"2024041206144034400_jiad205-B2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMsr1513109","article-title":"After Ebola in West Africa\u2014unpredictable risks, preventable epidemics","volume":"375","author":"WHO Ebola Response Team","year":"2016","journal-title":"N Engl J Med"},{"key":"2024041206144034400_jiad205-B3","author":"World Health Organization","year":"2020"},{"key":"2024041206144034400_jiad205-B4","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2024041206144034400_jiad205-B5","author":"World Health Organization","year":"2022"},{"key":"2024041206144034400_jiad205-B6","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1056\/NEJMc2120183","article-title":"Detection of Marburg virus disease in Guinea","volume":"386","author":"Koundouno","year":"2022","journal-title":"N Engl J Med"},{"key":"2024041206144034400_jiad205-B7","doi-asserted-by":"crossref","first-page":"o1797","DOI":"10.1136\/bmj.o1797","article-title":"Ghana declares its first outbreak of Marburg virus disease after two deaths","volume":"378","author":"Hussain","year":"2022","journal-title":"BMJ"},{"key":"2024041206144034400_jiad205-B8","author":"World Health Organization","year":"2023"},{"key":"2024041206144034400_jiad205-B9","author":"World Health Organization","year":"2023"},{"key":"2024041206144034400_jiad205-B10","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.molmed.2017.07.002","article-title":"Clinical evaluation of Ebola virus disease therapeutics","volume":"23","author":"Liu","year":"2017","journal-title":"Trends Mol Med"},{"key":"2024041206144034400_jiad205-B11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"2024041206144034400_jiad205-B12","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J Infect Dis"},{"key":"2024041206144034400_jiad205-B13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"2024041206144034400_jiad205-B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chom.2018.12.004","article-title":"Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection","volume":"25","author":"Wec","year":"2019","journal-title":"Cell Host Microbe"},{"key":"2024041206144034400_jiad205-B15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"2024041206144034400_jiad205-B16","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1016\/j.cell.2021.09.035","article-title":"Pan-ebolavirus protective therapy by two multifunctional human antibodies","volume":"184","author":"Gilchuk","year":"2021","journal-title":"Cell"},{"key":"2024041206144034400_jiad205-B17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cell.2022.02.023","article-title":"Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses","volume":"185","author":"Milligan","year":"2022","journal-title":"Cell"},{"key":"2024041206144034400_jiad205-B18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41467-018-08040-w","article-title":"Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates","volume":"10","author":"Brannan","year":"2019","journal-title":"Nat Commun"},{"key":"2024041206144034400_jiad205-B19","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1038\/srep06881","article-title":"Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus","volume":"4","author":"Audet","year":"2014","journal-title":"Sci Rep"},{"key":"2024041206144034400_jiad205-B20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \u201cTrojan horse\u201d bispecific-antibody strategy for broad protection against ebolaviruses","volume":"354","author":"Wec","year":"2016","journal-title":"Science"},{"key":"2024041206144034400_jiad205-B21","doi-asserted-by":"crossref","first-page":"329ra33","DOI":"10.1126\/scitranslmed.aad9875","article-title":"Two-mAb cocktail protects macaques against the Makona variant of Ebola virus","volume":"8","author":"Qiu","year":"2016","journal-title":"Sci Transl Med"},{"key":"2024041206144034400_jiad205-B22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clim.2011.08.008","article-title":"Characterization of Zaire ebolavirus glycoprotein\u2013specific monoclonal antibodies","volume":"141","author":"Qiu","year":"2011","journal-title":"Clin Immunol"},{"key":"2024041206144034400_jiad205-B23","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"2024041206144034400_jiad205-B24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","article-title":"Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein hr2-mper region","volume":"3","author":"Flyak","year":"2018","journal-title":"Nat Microbiol"},{"key":"2024041206144034400_jiad205-B25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","article-title":"Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein","volume":"49","author":"Gilchuk","year":"2018","journal-title":"Immunity"},{"key":"2024041206144034400_jiad205-B26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","article-title":"Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans","volume":"27","author":"Rijal","year":"2019","journal-title":"Cell Rep"},{"key":"2024041206144034400_jiad205-B27","doi-asserted-by":"crossref","first-page":"20514","DOI":"10.1038\/srep20514","article-title":"Discovery of an antibody for pan-ebolavirus therapy","volume":"6","author":"Furuyama","year":"2016","journal-title":"Sci Rep"},{"key":"2024041206144034400_jiad205-B28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","article-title":"Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability","volume":"169","author":"Zhao","year":"2017","journal-title":"Cell"},{"key":"2024041206144034400_jiad205-B29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/JVI.02172-15","article-title":"Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein","volume":"90","author":"Keck","year":"2016","journal-title":"J Virol"},{"key":"2024041206144034400_jiad205-B30","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17460441.2018.1527827","article-title":"Small animal models of filovirus disease: recent advances and future directions","volume":"13","author":"Cross","year":"2018","journal-title":"Expert Opin Drug Discov"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad205\/50542022\/jiad205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S691\/57219361\/jiad205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S691\/57219361\/jiad205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:15:03Z","timestamp":1712902503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_7\/S691\/7191932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":30,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2023,6,8]]},"published-print":{"date-parts":[[2023,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad205","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,6,8]]}}}